The Medicines Company (NASDAQ:MDCO) Weekly Ratings on May 17, 2018

May 17, 2018 - By Kevin Carney

The Medicines Company (NASDAQ:MDCO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.25. That’s change of 0.47, from 2017Q3’s 0.78. 26 investors sold all, 51 reduced holdings as The Medicines Company ratio increased. 68 increased positions while 28 funds amassed positions. Funds hold 89.44 million shares thus 5.03% more from 2017Q3’s 85.15 million shares.
14,178 were reported by Public Employees Retirement Association Of Colorado. Pointstate Cap Lp holds 2.04M shs or 0.54% of its capital. Parametric Portfolio Associate Limited reported 113,010 shs stake. Hightower Advsr Ltd Company invested 0% of its capital in The Medicines Company (NASDAQ:MDCO). University Of Notre Dame Du Lac has invested 1.77% in The Medicines Company (NASDAQ:MDCO). Alphaone Serv Ltd Llc has 0.01% invested in The Medicines Company (NASDAQ:MDCO). Comerica Commercial Bank holds 66,376 shs or 0.01% of its capital. Bancshares Of Montreal Can holds 1,897 shs or 0% of its capital. Atria Investments Ltd Liability reported 0.01% stake. Camber Capital Mngmt Ltd Company, a Massachusetts-based fund reported 1.60 million shs. Eagle Asset Mgmt Inc has 0.12% invested in The Medicines Company (NASDAQ:MDCO) for 807,720 shs. Us Bancorporation De has invested 0% of its capital in The Medicines Company (NASDAQ:MDCO). California State Teachers Retirement System holds 108,795 shs. Connecticut-based Point72 Asset Mgmt L P has invested 0% in The Medicines Company (NASDAQ:MDCO). Credit Suisse Ag, Switzerland-based fund reported 75,641 shs.

The Medicines Company registered $783,400 net activity with 1 insider buy and 3 sales since December 7, 2017. $574,200 worth of The Medicines Company (NASDAQ:MDCO) was sold by KESSLER ARMIN M. CROUSE WILLIAM also sold $241,950 worth of The Medicines Company (NASDAQ:MDCO) on Wednesday, March 21. $3.71M worth of The Medicines Company (NASDAQ:MDCO) shs were sold by MEANWELL CLIVE.

The Medicines Company (NASDAQ:MDCO) Ratings Coverage

In total 3 analysts cover Medicines Co (NASDAQ:MDCO). “Buy” rating has 3, “Sell” are 0, while 0 are “Hold”. (NASDAQ:MDCO) has 100% bullish analysts. 6 are the (NASDAQ:MDCO)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Thursday, March 22 the firm has “Buy” rating by Oppenheimer given. On Thursday, February 22 the firm earned “Hold” rating by Oppenheimer. On Monday, January 22 the firm earned “Buy” rating by Citigroup. On Wednesday, November 29 the rating was upgraded by Oppenheimer to “Buy”. On Monday, January 15 Oppenheimer maintained The Medicines Company (NASDAQ:MDCO) rating. Oppenheimer has “Buy” rating and $50.0 target. Listed here are The Medicines Company (NASDAQ:MDCO) PTs and latest ratings.

22/03/2018 Broker: Oppenheimer Rating: Buy Maintain
22/02/2018 Broker: Oppenheimer Rating: Hold New Target: $50.0 Maintain
24/01/2018 Broker: J.P. Morgan Rating: Buy New Target: $45.0
22/01/2018 Broker: Citigroup Rating: Buy New Target: $40.0 Upgrade
15/01/2018 Broker: Oppenheimer Rating: Buy New Target: $50.0 Maintain
29/11/2017 Broker: Oppenheimer Rating: Buy New Target: $50.0 Upgrade

Ticker’s shares touched $32.2 during the last trading session after 0.22% change.Currently The Medicines Company is downtrending after 34.73% change in last May 17, 2017. MDCO has 288,319 shares volume. MDCO underperformed the S&P500 by 46.28%.

The Medicines Company, a biopharmaceutical company, provides medicines for patients in acute and intensive care hospitals worldwide.The firm is worth $2.37 billion. The firm markets Angiomax, an intravenous direct thrombin inhibitor used as an anticoagulant in combination with aspirin in patients with unstable angina undergoing percutaneous transluminal coronary angioplasty, and for patients undergoing percutaneous coronary intervention; Ionsys, a fentanyl iontophoretic transdermal system for the short term management of acute postoperative pain for adults requiring opioid analgesia in the hospital.Currently it has negative earnings. It also markets Minocin IV, an intravenous formulation of a tetracycline-class antibiotic used for the treatment of infections due to susceptible strains of designated gram-negative bacteria; and Orbactiv, an intravenous antibiotic used for the treatment of adult patients with acute bacterial skin and skin structure infections, or caused or suspected to be caused by susceptible isolates of designated gram-positive microorganisms.

For more The Medicines Company (NASDAQ:MDCO) news posted briefly go to: Fool.com, Seekingalpha.com, Fool.com, Streetinsider.com or Streetinsider.com. The titles are as follows: “Alnylam Looks Forward” posted on May 08, 2018, “The Medicines (MDCO) Q1 2018 Results – Earnings Call Transcript” on April 25, 2018, “Is Alnylam Pharmaceuticals, Inc. (ALNY) a Buy?” with a publish date: May 17, 2018, “Einhorn’s Greenlight Capital Enters Office Depot (ODP), Abercrombie & Fitch (ANF) (more…) – 13F” and the last “Medicines Co. (MDCO) ORION-1 Phase II Study Shows Significant Reductions in Potentially Harmful Subtypes of Bad …” with publication date: May 07, 2018.

The Medicines Company (NASDAQ:MDCO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.